Efficacy and safety of degludec versus Glargine in Type 2 Diabetes

New England Journal of Medicine

Volumn 377, Issue 8, 2017, Pages 723-732

  Marso, Steven P ^a   Mcguire, Darren K ^b   Zinman, Bernard ^c   Poulter, Neil R ^d   Emerson, Scott S ^e   Pieber, Thomas R ^f   Pratley, Richard E ^g   Haahr, Poul Martin ^h   Lange, Martin ^h   Brown Frandsen, Kirstine ^h   Moses, Alan ^h   Skibsted, Simon ^h   Kvist, Kajsa ^h   Buse, John B ⁱ  

^a Research Medical Center Brookside Campus   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g FLORIDA HOSPITAL   (United States)

^h NOVO NORDISK A S   (Denmark)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BENIGN NEOPLASM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANALYSIS; BLOOD; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; FEMALE; INCIDENCE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN GLARGINE; INSULIN, LONG-ACTING; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED;

EID: 85027852950     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1615692     Document Type: Article

References (28)

1. Dailey G. Overall mortality in diabetes mellitus: Where do we stand today? Diabetes Technol Ther 2011; 13: Suppl 1: S65-S74.
2. Munnee K, Bundhun PK, Quan H, Tang Z. Comparing the clinical outcomes between insulin-Treated and non-insulintreated patients with type 2 diabetes mellitus after coronary artery bypass surgery: A systematic review and meta-Analysis. Medicine (Baltimore) 2016; 95(10): E3006.
3. Li J, Tong Y, Zhang Y, et al. Effects on all-cause mortality and cardiovascular outcomes in patients with type 2 diabetes by comparing insulin with oral hypoglycemic agent therapy: A meta-Analysis of randomized controlled trials. Clin Ther 2016; 38(2): 372-386.e6.
4. The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-28.
5. Tresiba prescribing information. 2015 (http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/203314lbl.pdf).
6. Tresiba summary of product characteristics. 2015 (http://www .medicines .org .uk/emc/medicine/27360).
7. Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab 2017; 19: 3-12.
8. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-Analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175-84.
9. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-64.
10. Marso SP, McGuire DK, Zinman B, et al. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. Am Heart J 2016; 179: 175-83.
11. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-4.
12. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. J Postgrad Med 2001; 47: 199-203.
13. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36: 1384-95.
14. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
16. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
17. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
18. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes: guidance for industry. December 2008 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf).
19. Schnell O, Rydén L, Standl E, Ceriello A. Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol 2016; 15: 139.
20. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-20.
21. Wysham C, Bhargava A, Chaykin L, et al. SWITCH 2: Reduced risk of hypoglycaemia with insulin degludec vs insulin glargine U100 in a type 2 diabetes population on basal insulin: A randomised, double-blind, crossover trial. Diabetologia 2016; 59: Suppl1: S43. abstract.
22. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-8.
23. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340: b5444.
24. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care 2011; 34: Suppl 2: S132-S137.
25. Graveling AJ, Frier BM. Hypoglycaemia: An overview. Prim Care Diabetes 2009; 3: 131-9.
26. Wittes J. On looking at subgroups. Circulation 2009; 119: 912-5.
27. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions, version 5.1.0. Sect. 9.6.2., 9.6.6. The Cochrane Collaboration, 2011 http://handbook.cochrane.org).
28. Wittes J. Why is this subgroup different from all other subgroups? Thoughts on regional differences in randomized clinical trials. In: Fleming TR, Weir BS, eds. Proceedings of the Fourth Seattle Symposium in Biostatistics: clinical trials. New York: Springer Science, 2013: 95- 115.